{"pmid":32433641,"title":"Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19.","text":["Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19.","Hypertens Res","Furuhashi, Masato","Moniwa, Norihito","Takizawa, Hideki","Ura, Nobuyuki","Shimamoto, Kazuaki","32433641"],"journal":"Hypertens Res","authors":["Furuhashi, Masato","Moniwa, Norihito","Takizawa, Hideki","Ura, Nobuyuki","Shimamoto, Kazuaki"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32433641","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1038/s41440-020-0478-1","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667342288108388352,"score":9.490897,"similar":[{"pmid":32274522,"pmcid":"PMC7142323","title":"Inhibitors of the renin-angiotensin system and SARS-CoV-2 infection.","text":["Inhibitors of the renin-angiotensin system and SARS-CoV-2 infection.","Herz","Kessler, Thorsten","Schunkert, Heribert","32274522"],"journal":"Herz","authors":["Kessler, Thorsten","Schunkert, Heribert"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32274522","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s00059-020-04920-4","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491671543810,"score":69.55324},{"pmid":32409434,"title":"Renin-angiotensin system inhibitors in COVID-19.","text":["Renin-angiotensin system inhibitors in COVID-19.","Concerns have been raised about the potential for renin-angiotensin system (RAS) inhibitors to upregulate expression of angiotensin-converting enzyme 2 (ACE2) and thus increase susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry. Currently, there is no evidence that even if RAS inhibitors increase expression and activity of ACE2, that they would increase the risk of SARS-CoV-2 infection by facilitating greater viral entry or worsen outcomes in patients with COVID-19. At this time, there is no clinical evidence to suggest that treatment with RAS inhibitors should be discontinued in stable patients with COVID-19. In hospitalized patients with severe COVID-19, decisions about these medications should be based on clinical condition, including hemodynamic status and renal function.","Cleve Clin J Med","Thomas, George","32409434"],"abstract":["Concerns have been raised about the potential for renin-angiotensin system (RAS) inhibitors to upregulate expression of angiotensin-converting enzyme 2 (ACE2) and thus increase susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry. Currently, there is no evidence that even if RAS inhibitors increase expression and activity of ACE2, that they would increase the risk of SARS-CoV-2 infection by facilitating greater viral entry or worsen outcomes in patients with COVID-19. At this time, there is no clinical evidence to suggest that treatment with RAS inhibitors should be discontinued in stable patients with COVID-19. In hospitalized patients with severe COVID-19, decisions about these medications should be based on clinical condition, including hemodynamic status and renal function."],"journal":"Cleve Clin J Med","authors":["Thomas, George"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32409434","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3949/ccjm.87a.ccc009","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666989866099933184,"score":65.458626},{"pmid":32286678,"title":"Inhibitors of the renin-angiotensin system: The potential role in the pathogenesis of COVID-19.","text":["Inhibitors of the renin-angiotensin system: The potential role in the pathogenesis of COVID-19.","Coronavirus disease 2019 (COVID-19), which initially began in China, has spread to other countries of Asia, Europe, America, Africa and Oceania, with the number of confirmed cases and suspected cases increasing each day. According to recently published research, it was found that the majority of the severe cases were elderly, and many of them had at least one chronic disease, especially cardiovascular diseases. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) are the most widely used drugs for cardiovascular diseases. The clinical effect of ACEIs/ARBs on patients with COVID-19 is still uncertain. This paper describes their potential role in the pathogenesis of COVID-19, which may provide useful in the advice of cardiologists and physicians.","Cardiol J","Huang, Ziyin","Jiang, Yufeng","Chen, Jingjing","Zhou, Yafeng","32286678"],"abstract":["Coronavirus disease 2019 (COVID-19), which initially began in China, has spread to other countries of Asia, Europe, America, Africa and Oceania, with the number of confirmed cases and suspected cases increasing each day. According to recently published research, it was found that the majority of the severe cases were elderly, and many of them had at least one chronic disease, especially cardiovascular diseases. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) are the most widely used drugs for cardiovascular diseases. The clinical effect of ACEIs/ARBs on patients with COVID-19 is still uncertain. This paper describes their potential role in the pathogenesis of COVID-19, which may provide useful in the advice of cardiologists and physicians."],"journal":"Cardiol J","authors":["Huang, Ziyin","Jiang, Yufeng","Chen, Jingjing","Zhou, Yafeng"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32286678","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.5603/CJ.a2020.0056","keywords":["2019-ncov","covid-19","angiotensin-converting enzyme inhibitors","renin-angiotensin system"],"locations":["China","America"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491323416576,"score":65.02257},{"pmid":32425432,"pmcid":"PMC7220966","title":"Renin-Angiotensin System Inhibitors and COVID-19: Potential Therapeutics Rather Than Perpetrators.","text":["Renin-Angiotensin System Inhibitors and COVID-19: Potential Therapeutics Rather Than Perpetrators.","Acta Cardiol Sin","Wang, Tzung-Dau","32425432"],"journal":"Acta Cardiol Sin","authors":["Wang, Tzung-Dau"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425432","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.6515/ACS.202005_36(3).20200430A","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667352728925372416,"score":65.02257},{"pmid":32332039,"title":"Renin-angiotensin-aldosterone system inhibitors and COVID-19.","text":["Renin-angiotensin-aldosterone system inhibitors and COVID-19.","CMAJ","Quinn, Kieran L","Fralick, Michael","Zipursky, Jonathan S","Stall, Nathan M","32332039"],"journal":"CMAJ","authors":["Quinn, Kieran L","Fralick, Michael","Zipursky, Jonathan S","Stall, Nathan M"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32332039","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1503/cmaj.200619","e_drugs":["Aldosterone"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138493934370817,"score":62.768917}]}